

## Q&A Feb 9 2024

Question for later: I recently had a preterm baby and the hospital had me fill out a survey with the client to determine whether the baby is eligible for RSV prophylaxis. One of the questions was about whether anyone in the household has eczema- and I was wondering what is the relevancy/correlation.

[ANSWERED LIVE](#)

12:27:32 From Jenny Limoges to Everyone:

Can you please review where people can access these prophylaxis options, and also what the cost is to families (as they may not be covered by AHS). We are noticing that Pharmacies in our rural communities are starting to charge pregnant people for DTAP because the AHS funded doses are out-of-stock. Is this funding issue something that may follow the RSV immunization in pregnancy, or post-birth (RSV prophylaxis for infants).

[ANSWERED LIVE](#)

12:35:14 From Ayesha Haque to Everyone:

Does Abrysvo follow the same monthly schedule?

[ANSWERED LIVE](#)

12:36:23 From Morgan Robins to Everyone:

Question for later, can pregnant people get the TDAP vaccine and Abrysvo at the same time or do they need to be separated by a certain time

[ANSWERED LIVE](#)

12:50:19 From Victoria Malamant to Everyone:

Just to clarify, the new vaccines are not covered by OHIP for healthy newborns and pregnant people?

[We are still waiting to hear about details re: provincial and territorial coverage for both the vaccination during pregnancy and the monoclonal antibody immunization for infants.](#)

12:50:33 From Julie Doldersum to Host and Panelists:

If pregnant person receives ABRYSSVO between 32-36 weeks, will babe also require BEYFORTUS at birth or are they mutually exclusive?

[ANSWERED LIVE](#)

12:51:08 From Hannah Sinclair to Host and Panelists:

Are family doctors currently vaccinating pregnant people with Abrysvo? Is it readily available?

[Not yet in Canada](#)

12:52:08 From Deanna Deys to Everyone:

Will administration be recommended for both the vaccination in pregnancy and infant vaccination

**ANSWERED LIVE**

12:54:43 From Ayeshah Haque to Everyone:

Do you know the efficacy rates for each product?

**SEE PRODUCT MONOGRAPH DETAILS BELOW:**

Beyfortus product monograph

[https://pdf.hres.ca/dpd\\_pm/00070439.PDF](https://pdf.hres.ca/dpd_pm/00070439.PDF)

Abrysvo product monograph

[https://pdf.hres.ca/dpd\\_pm/00073900.PDF](https://pdf.hres.ca/dpd_pm/00073900.PDF)

**Table 7 Analysis of primary endpoint: Efficacy in term and preterm infants against MA RSV LRTI through 150 days post dose, Study 3 and MELODY (Primary Cohort)**

Group	Treatment	N	Incidence % (n)	Efficacy <sup>a</sup> (95% CI) <sup>a</sup>
Very and moderately preterm GA ≥29 to <35 weeks; Study 3	BEYFORTUS	969	2.6 (25)	70.1% (52.3, 81.2) p<0.0001 <sup>b</sup>
	Placebo	484	9.5 (46)	
Term and late preterm GA ≥35 weeks; MELODY (Primary Cohort)	BEYFORTUS	994	1.2 (12)	74.5% (49.6, 87.1) p<0.0001 <sup>b</sup>
	Placebo	496	5.0 (25)	

<sup>a</sup> Based on relative risk reduction versus placebo. The relative risk reduction and 95% CI were calculated using modified Poisson regression with robust variance including stratification factors (hemisphere and age at randomization).

<sup>b</sup> Statistically significant.

Vaccine efficacy information is presented in **Tables 11 to 13**.

**Table 11 - Vaccine efficacy of Abrysvo against severe medically attended lower respiratory tract illness caused by RSV - infants from birth through 6 months of age by active immunization of pregnant individuals – Study C3671008**

Time period	Abrysvo Number of cases N=3,495 <sup>b</sup>	Placebo Number of cases N=3,480	VE % (CI) <sup>a</sup>
90 days	6	33	81.8 (40.6, 96.3)
120 days	12	46	73.9 (45.6, 88.8)
150 days	16	55	70.9 (44.5, 85.9)
180 days	19	62	69.4 (44.3, 84.1)

CI = confidence interval; VE = vaccine efficacy

<sup>a</sup> 99.5% CI at 90 days; 97.58% CI at later intervals

<sup>b</sup> Evaluable efficacy population